Celldex Therapeutics Valuation
| CLDX Stock | USD 23.00 0.06 0.26% |
At this time, the firm appears to be undervalued. Celldex Therapeutics shows a prevailing Real Value of $30.7 per share. The current price of the firm is $23.0. Our model approximates the value of Celldex Therapeutics from analyzing the firm fundamentals such as Operating Margin of (98.59) %, return on equity of -0.32, and Shares Outstanding of 66.45 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Celldex Therapeutics' valuation include:
Price Book 2.5542 | Enterprise Value | Enterprise Value Ebitda (17.34) | Price Sales 588.0485 | Enterprise Value Revenue 364.654 |
Undervalued
Today
Please note that Celldex Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Celldex Therapeutics is based on 3 months time horizon. Increasing Celldex Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Celldex Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Celldex Stock. However, Celldex Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 23.0 | Real 30.7 | Target 53.36 | Hype 23.26 | Naive 23.43 |
The intrinsic value of Celldex Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Celldex Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Celldex Therapeutics helps investors to forecast how Celldex stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Celldex Therapeutics more accurately as focusing exclusively on Celldex Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Celldex Therapeutics' intrinsic value based on its ongoing forecasts of Celldex Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Celldex Therapeutics' closest peers.
Celldex Therapeutics Cash |
|
Celldex Revenue by Product
Celldex Therapeutics Total Value Analysis
Celldex Therapeutics is currently forecasted to have valuation of 947.74 M with market capitalization of 1.53 B, debt of 3.81 M, and cash on hands of 356.82 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Celldex Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
947.74 M | 1.53 B | 3.81 M | 356.82 M |
Celldex Therapeutics Investor Information
About 100.0% of the company shares are held by institutions such as insurance companies. The book value of Celldex Therapeutics was currently reported as 9.01. The company recorded a loss per share of 3.38. Celldex Therapeutics last dividend was issued on the 11th of February 2019. The entity had 1:15 split on the 11th of February 2019. Based on the key indicators related to Celldex Therapeutics' liquidity, profitability, solvency, and operating efficiency, Celldex Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Celldex Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Celldex Therapeutics has an asset utilization ratio of 0.89 percent. This suggests that the Company is making $0.00886 for each dollar of assets. An increasing asset utilization means that Celldex Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Celldex Therapeutics Profitability Analysis
Based on Celldex Therapeutics' profitability indicators, Celldex Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Celldex Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 1985-09-30 | Previous Quarter -56.6 M | Current Value -67 M | Quarterly Volatility 16.2 M |
For Celldex Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Celldex Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Celldex Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Celldex Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Celldex Therapeutics over time as well as its relative position and ranking within its peers.
Celldex Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Celldex Therapeutics is estimated to be -1.0575 with future projections ranging from a low of -1.22 to a high of -0.96. Celldex Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -3.38. Please be aware that the consensus of earnings estimates for Celldex Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Celldex Therapeutics Earnings Estimation Breakdown
The calculation of Celldex Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Celldex Therapeutics is estimated to be -1.0575 with the future projection ranging from a low of -1.22 to a high of -0.96. Please be aware that this consensus of annual earnings estimates for Celldex Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.22 Lowest | Expected EPS | -0.96 Highest |
Celldex Therapeutics Earnings Projection Consensus
Suppose the current estimates of Celldex Therapeutics' value are higher than the current market price of the Celldex Therapeutics stock. In this case, investors may conclude that Celldex Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Celldex Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 16 | 88.87% | 0.0 | -1.0575 | -3.38 |
Celldex Therapeutics Ownership Allocation
The majority of Celldex Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Celldex Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Celldex Therapeutics. Please pay attention to any change in the institutional holdings of Celldex Therapeutics as this could imply that something significant has changed or is about to change at the company.Celldex Therapeutics Profitability Analysis
The company reported the previous year's revenue of 7.02 M. Net Loss for the year was (157.86 M) with loss before overhead, payroll, taxes, and interest of (214.08 M).About Celldex Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Celldex Therapeutics. We calculate exposure to Celldex Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Celldex Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -140.9 M | -133.8 M | |
| Pretax Profit Margin | (25.86) | (24.57) | |
| Operating Profit Margin | (31.96) | (30.36) | |
| Net Loss | (25.86) | (24.57) | |
| Gross Profit Margin | (25.64) | (24.36) |
Celldex Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Celldex Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Celldex we look at many different elements of the entity such as Celldex's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Celldex Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Celldex Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Celldex Therapeutics' worth.Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.